GlobeNewsWire
14 Jun 2026, 22:05 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
ZW191 demonstrated a confirmed overall response rate (cORR) of 78.6% in patients with FRα-positive platinum-resistant ovarian cancer. — High efficacy in a difficult-to-treat cancer population is a primary driver for biotech valuation and future FDA approval prospects.
+0.80ZW191 showed anti-tumor activity in FRα-negative tumors, with a cORR of 47.4% in ovarian and 40.0% in endometrial cancer patients. — Expanding the addressable patient population beyond FRα-positive cases significantly increases the potential commercial market size.
+0.60The study reported a median progression-free survival of 7.6 months and that the median duration of response had not yet been reached. — Positive durability data suggests a sustained clinical benefit, which is critical for moving from Phase 1 to pivotal trials.
+0.50Continue reading
6 related stories
Search tags
Grade ≥3 treatment-emergent adverse events occurred in 55% of patients, with 20% discontinuing treatment due to adverse events. — While described as 'manageable,' a high rate of severe adverse events and discontinuations presents a potential regulatory risk or limiting factor for use.
-0.30Enrollment for Part 2a (dose optimization in ~60 PROC patients) has been completed, with data expected at a future meeting. — Completion of enrollment is a positive operational milestone that sets the stage for the next catalyst event.
+0.20Which stocks this story touches
The company presented positive Phase 1 clinical data demonstrating compelling anti-tumor activity and a manageable safety profile for ZW191.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
6h ago
